Skip to main content
. 2011 Sep 28;23(5):1121–1129. doi: 10.1093/annonc/mdr412

Figure 2.

Figure 2.

Disease-free survival (A) and overall survival (B) by treatment. D, docetaxel; EC, epirubicin plus cyclophosphamide.